Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more
NCT07042100 · Advanced Solid Tumors
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT07087197 · Metastatic Solid Tumors
NCT07335497 · Locally Advanced / Metastatic Solid Tumors
Pfizer Investigational Site
Nashville, Tennessee
Pfizer Investigational Site
Leuven
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions